Association of Gene Variants With Incident Myocardial Infarction in the Cardiovascular Health Study

Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 6). 01/2008; 28(1):173-9. DOI: 10.1161/ATVBAHA.107.153981
Source: PubMed


We asked whether single nucleotide polymorphisms (SNPs) that had been nominally associated with cardiovascular disease in antecedent studies were also associated with cardiovascular disease in a population-based prospective study of 4522 individuals aged 65 or older.
Based on antecedent studies, we prespecified a risk allele and an inheritance model for each of 74 SNPs. We then tested the association of these SNPs with myocardial infarction (MI) in the Cardiovascular Health Study (CHS). The prespecified risk alleles of 8 SNPs were nominally associated (1-sided P<0.05) with increased risk of MI in White CHS participants. The false discovery rate for these 8 was 0.43, suggesting that about 4 of these 8 are likely to be true positives. The 4 of these 8 SNPs that had the strongest evidence for association with cardiovascular disease before testing in CHS (association in 3 antecedent studies) were in KIF6 (CHS HR=1.29; 90%CI 1.1 to 1.52), VAMP8 (HR=1.2; 90%CI 1.02 to 1.41), TAS2R50 (HR=1.13; 90%CI 1 to 1.27), and LPA (HR=1.62; 90%CI 1.09 to 2.42).
Although most of the SNPs investigated were not associated with MI in CHS, evidence from this investigation combined with previous studies suggests that 4 of these SNPs are likely associated with MI.

Full-text preview

Available from:
  • Source
    • "Since tHcy and CRP have demonstrated associations with cardiovascular disease [29] [30] and AD [14] [15] [16] [17] [18], we sought to investigate whether KIF6 719Arg carrier status is associated with tHcy and CRP in a group of clinically diagnosed AD and aMCI patients. Since KIF6 719Arg carrier status has been previously associated with cardiovascular disease [1] [2] [3] [4] [5] [6], investigating its associations with tHcy and CRP in AD is of interest given the proposed cardiovascular pathways for AD pathogenesis [31] [32] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent research has demonstrated associations between statin use, KIF6 719Arg carrier status, and cholesterol levels and amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) patients. The association between 719Arg carrier status with homocysteine (tHcy) and c-reactive protein (CRP) levels in aMCI and AD has not been previously investigated. Data from 175 aMCI and AD patients were used for the analysis. 719Arg carriers had significantly lower levels of tHcy than noncarriers (P = 0.02). No significant difference in CRP levels between 719Arg carriers and noncarriers was present (P = 0.37). Logistic regression yielded no significant effect for 719Arg status on CRP [OR = 1.79 (0.85, 3.83), P = 0.13] but did demonstrate a significant effect for tHcy [OR = 0.44 (0.23, 0.83), P = 0.01] after adjusting for ApoE ε4 carrier status, age, gender, and statin use. This study is the first to explore the relationship between KIF6 719Arg carrier status with tHcy and CRP levels. 719Arg carriers were more likely to have normal tHcy levels after adjusting for ApoE ε4 status, age, gender, and statin use. These results suggest that the KIF6 gene might influence cardiovascular pathways associated with AD.
    International Journal of Alzheimer's Disease 12/2013; 2013:242303. DOI:10.1155/2013/242303
  • Source
    • "Interestingly, taste receptors are upregulated in several conditions where specific nutrients are depleted [5], [32], and a single nucleotide polymorphism in a human TAS2R has been linked to deficits in glucose homeostasis [33]. Similarly, gene variants in TAS2Rs are related to disease – a polymorphism in TAS2R38 contributes to an increased susceptibility to respiratory infection [34] and a mutation in TAS2R50 has been associated with cardiovascular disease in several population-based prospective studies [35], [36], but the mechanisms by which the variants of these TAS2 genes influence the pathophysiology of disease are mostly unknown. Although the present findings do not discriminate between increased TAS2 expression in a subpopulation of cells versus an increase in the number of cells expressing the receptor, the cardiac expression of taste GPCRs raises the possibility of a direct effect, beyond oral sensation [37]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: G protein-coupled receptors (GPCRs) are critical for cardiovascular physiology. Cardiac cells express >100 nonchemosensory GPCRs, indicating that important physiological and potential therapeutic targets remain to be discovered. Moreover, there is a growing appreciation that members of the large, distinct taste and odorant GPCR families have specific functions in tissues beyond the oronasal cavity, including in the brain, gastrointestinal tract and respiratory system. To date, these chemosensory GPCRs have not been systematically studied in the heart. We performed RT-qPCR taste receptor screens in rodent and human heart tissues that revealed discrete subsets of type 2 taste receptors (TAS2/Tas2) as well as Tas1r1 and Tas1r3 (comprising the umami receptor) are expressed. These taste GPCRs are present in cultured cardiac myocytes and fibroblasts, and by in situ hybridization can be visualized across the myocardium in isolated cardiac cells. Tas1r1 gene-targeted mice (Tas1r1 (Cre) /Rosa26 (tdRFP) ) strikingly recapitulated these data. In vivo taste receptor expression levels were developmentally regulated in the postnatal period. Intriguingly, several Tas2rs were upregulated in cultured rat myocytes and in mouse heart in vivo following starvation. The discovery of taste GPCRs in the heart opens an exciting new field of cardiac research. We predict that these taste receptors may function as nutrient sensors in the heart.
    PLoS ONE 05/2013; 8(5):e64579. DOI:10.1371/journal.pone.0064579 · 3.23 Impact Factor
  • Source
    • "There has been considerable debate within the cardiovascular community regarding the role of kinesin-like protein 6 (Kif6) in coronary artery disease. Initial reports using a candidate gene based approach in several atherosclerosis population cohorts observed an increase risk of adverse coronary events in carriers of the rs20455 C variant in the KIF6 gene which leads to a Trp719Arg substitution in the Kif6 protein [1], [2], [3], [4]. These findings were controversial and refuted by a large GWAS meta-analysis using 19 case-control studies [5] where cases were defined either by a history of prior myocardial infarction and/or the presence of coronary artery disease at angiography. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A KIF6 variant in man has been reported to be associated with adverse cardiovascular outcomes after myocardial infarction. No clear biological or physiological data exist for Kif6. We sought to investigate the impact of a deleterious KIF6 mutation on cardiac function in mice. Kif6 mutant mice were generated and verified. Cardiac function was assessed by serial echocardiography at baseline, after ageing and after exercise. Lipid levels were also measured. No discernable adverse lipid or cardiac phenotype was detected in Kif6 mutant mice. These data suggest that dysfunction of Kif6 is linked to other more complex biological/biochemical parameters or is unlikely to be of material consequence in cardiac function.
    PLoS ONE 01/2013; 8(1):e54636. DOI:10.1371/journal.pone.0054636 · 3.23 Impact Factor
Show more